A study of JNJ-64042056 in participants with preclinical Alzheimer's disease

You may qualify if

• 55 to 75 years of age, inclusive, at randomisation visit.
• Elevated brain tau pathology defined as Braak 3 ROI SUVR > 1.1 on a screening tau PET scan, reviewed centrally by a qualified reader.
• CDR global score of 0 at screening and baseline.
• MMSE ≥27 (with educational adjustment).
• Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening.

You're excluded if

• MRI evidence of any brain disease or intracranial pathology other than potential very early signs of AD or typical age-related changes, which in the opinion of the investigator or the central imaging reader and/or the sponsor, may affect cognition.
• History consistent with or known autosomal dominant AD.
• Fulfills diagnostic criteria for Alzheimer’s Dementia or non-Alzheimer’s Dementia, including, but not limited to Frontotemporal Dementia (FTD), Diffuse Lewy Body Dementia (DLBD), Vascular Dementia (VAD), alcoholic dementia, Parkinson’s dementia, Korsakov, Creutzfeldt-Jakob or other prion diseases, Posterior Cortical Atrophy.
• Diagnosis ofMild Cognitive Impairment (MCI)
• Presence of any neurological, psychiatric, or medical conditions associated with a longterm risk of significant cognitive impairment or dementia

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2024-06-04